Jan 2021 • Cancer Discovery
Sushil Kumar, Zexian Zeng, Archis Bagati, Rong En Tay, Lionel A Sanz, Stella R Hartono, Yoshinaga Ito, Fieda Abderazzaq, Elodie Hatchi, Peng Jiang, Adam NR Cartwright, Olamide Olawoyin, Nathan D Mathewson, Jason W Pyrdol, Mamie Z Li, John G Doench, Matthew A Booker, Michael Y Tolstorukov, Stephen J Elledge, Frederic Chedin, X Shirley Liu, Kai W Wucherpfennig
A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise antitumor immune function. We discovered that inhibition of CARM1, an epigenetic enzyme and cotranscriptional activator, elicited beneficial antitumor activity in both cytotoxic T cells and tumor cells. In T cells, Carm1 inactivation substantially enhanced their antitumor function and preserved memory-like populations required for sustained antitumor immunity. In tumor cells, Carm1 inactivation induced a potent type 1 interferon response that sensitized resistant tumors to cytotoxic T cells. Substantially increased numbers of dendritic cells, CD8 T cells, and natural killer cells were present in Carm1-deficient tumors, and infiltrating CD8 T cells expressed low levels of exhaustion markers. Targeting of CARM1 with a small molecule elicited potent antitumor immunity and sensitized resistant tumors …
Show moreJan 2021 • bioRxiv
Wubing Zhang, Shourya S Roy Burman, Jiaye Chen, Katherine A Donovan, Yang Cao, Boning Zhang, Zexian Zeng, Yi Zhang, Dian Li, Eric S Fischer, Collin Tokheim, Xiaole Shirley Liu
Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cell’s endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed “degradability”, is largely unknown. Here, we developed a machine learning model, model-free analysis of protein degradability (MAPD), to predict degradability from features intrinsic to protein targets. MAPD shows accurate performance in predicting kinases that are degradable by TPD compounds [with an area under precision recall curve (AUPRC) of 0.759 and area under the receiver operating characteristic curve (AUROC) of 0.775] and is likely generalizable to independent non-kinase proteins. We found five features with statistical significance to achieve optimal prediction, with ubiquitination potential being the most predictive. By …
Show moreJan 2021 • Cancer Discovery
Sushil Kumar, Zexian Zeng, Archis Bagati, Rong En Tay, Lionel A Sanz, Stella R Hartono, Yoshinaga Ito, Fieda Abderazzaq, Elodie Hatchi, Peng Jiang, Adam NR Cartwright, Olamide Olawoyin, Nathan D Mathewson, Jason W Pyrdol, Mamie Z Li, John G Doench, Matthew A Booker, Michael Y Tolstorukov, Stephen J Elledge, Frederic Chedin, X Shirley Liu, Kai W Wucherpfennig
A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise anti-tumor immune function. We discovered that inhibition of Carm1, an epigenetic enzyme and co-transcriptional activator, elicited beneficial anti-tumor activity in both cytotoxic T cells and tumor cells. In T cells, Carm1 inactivation substantially enhanced their anti-tumor function and preserved memory-like populations required for sustained anti-tumor immunity. In tumor cells, Carm1 inactivation induced a potent type 1 interferon response that sensitized resistant tumors to cytotoxic T cells. Substantially increased numbers of dendritic cells, CD8 T cells and NK cells were present in Carm1-deficient tumors, and infiltrating CD8 T cells expressed low levels of exhaustion markers. Targeting of Carm1 with a small molecule elicited potent anti-tumor immunity and sensitized resistant tumors to checkpoint blockade …
Show moreJan 2021 • Cancer Discovery
Livius Penter, Satyen H Gohil, Caleb Lareau, Leif S Ludwig, Erin M Parry, Teddy Huang, Shuqiang Li, Wandi Zhang, Dimitri Livitz, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Laura Z Rassenti, Thomas J Kipps, Jennifer R Brown, Matthew S Davids, Donna S Neuberg, Kenneth J Livak, Vijay G Sankaran, Catherine J Wu
While cancers evolve during disease progression and in response to therapy, temporal dynamics remain difficult to study in humans due to the lack of consistent barcodes marking individual clones in vivo. We employ mitochondrial single-cell assay for transposase-accessible chromatin with sequencing to profile 163,279 cells from 9 patients with chronic lymphocytic leukemia (CLL) collected across disease course and utilize mitochondrial DNA (mtDNA) mutations as natural genetic markers of cancer clones. We observe stable propagation of mtDNA mutations over years in the absence of strong selective pressure indicating clonal persistence, but dramatic changes following tight bottlenecks including disease transformation and relapse post-therapy, paralleled by acquisition of copy number variants, changes in chromatin accessibility and gene expression. Furthermore, we link CLL subclones to distinct chromatin …
Show moreJan 2021 • Cancer Discovery
Sushil Kumar, Zexian Zeng, Archis Bagati, Rong En Tay, Lionel A Sanz, Stella R Hartono, Yoshinaga Ito, Fieda Abderazzaq, Elodie Hatchi, Peng Jiang, Adam NR Cartwright, Olamide Olawoyin, Nathan D Mathewson, Jason W Pyrdol, Mamie Z Li, John G Doench, Matthew A Booker, Michael Y Tolstorukov, Stephen J Elledge, Frederic Chedin, X Shirley Liu, Kai W Wucherpfennig
A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise anti-tumor immune function. We discovered that inhibition of Carm1, an epigenetic enzyme and co-transcriptional activator, elicited beneficial anti-tumor activity in both cytotoxic T cells and tumor cells. In T cells, Carm1 inactivation substantially enhanced their anti-tumor function and preserved memory-like populations required for sustained anti-tumor immunity. In tumor cells, Carm1 inactivation induced a potent type 1 interferon response that sensitized resistant tumors to cytotoxic T cells. Substantially increased numbers of dendritic cells, CD8 T cells and NK cells were present in Carm1-deficient tumors, and infiltrating CD8 T cells expressed low levels of exhaustion markers. Targeting of Carm1 with a small molecule elicited potent anti-tumor immunity and sensitized resistant tumors to checkpoint blockade …
Show moreJan 2021 • Frontiers in Immunology
Livius Penter, Satyen H Gohil, Catherine J Wu
Blood malignancies provide unique opportunities for longitudinal tracking of disease evolution following therapeutic bottlenecks and for the monitoring of changes in anti-tumor immunity. The expanding development of multi-modal single-cell sequencing technologies affords newer platforms to elucidate the mechanisms underlying these processes at unprecedented resolution. Furthermore, the identification of molecular events that can serve as in-vivo barcodes now facilitate the tracking of the trajectories of malignant and of immune cell populations over time within primary human samples, as these permit unambiguous identification of the clonal lineage of cell populations within heterogeneous phenotypes. Here, we provide an overview of the potential for chromosomal copy number changes, somatic nuclear and mitochondrial DNA mutations, single nucleotide polymorphisms, and T and B cell receptor sequences …
Show moreJan 2021 • bioRxiv
Wubing Zhang, Shourya S Roy Burman, Jiaye Chen, Katherine A Donovan, Yang Cao, Boning Zhang, Zexian Zeng, Yi Zhang, Dian Li, Eric S Fischer, Collin Tokheim, Xiaole Shirley Liu
Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cell9s endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed "degradability", is largely unknown. Recent systematic studies to map the degradable kinome have shown differences in degradation between kinases with similar drug-target engagement, suggesting yet unknown factors influencing degradability. We therefore developed a machine learning model, MAPD (Model-based Analysis of Protein Degradability), to predict degradability from protein features that encompass post-translational modifications, protein stability, protein expression and protein-protein interactions. MAPD shows accurate performance in predicting kinases that are degradable by TPD compounds (auPRC=0.759) and is likely generalizable to independent non-kinase proteins. We found five features with statistical significance to achieve optimal prediction, with ubiquitination potential being the most predictive. By structural modeling, we found that E2-accessible ubiquitination sites, but not lysine residues in general, are particularly associated with kinase degradability. Finally, we extended MAPD predictions to the entire proteome to find 964 disease-causing proteins, including 278 cancer genes, that may be tractable to TPD drug development.
Show moreJan 2021 • bioRxiv
Wubing Zhang, Shourya S Roy Burman, Jiaye Chen, Katherine A Donovan, Yang Cao, Boning Zhang, Zexian Zeng, Yi Zhang, Dian Li, Eric S Fischer, Collin Tokheim, Xiaole Shirley Liu
Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cell9s endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed "degradability", is largely unknown. Recent systematic studies to map the degradable kinome have shown differences in degradation between kinases with similar drug-target engagement, suggesting yet unknown factors influencing degradability. We therefore developed a machine learning model, MAPD (Model-based Analysis of Protein Degradability), to predict degradability from protein features that encompass post-translational modifications, protein stability, protein expression and protein-protein interactions. MAPD shows accurate performance in predicting kinases that are degradable by TPD compounds (auPRC=0.759) and is likely generalizable to independent non-kinase proteins. We found five features with statistical significance to achieve optimal prediction, with ubiquitination potential being the most predictive. By structural modeling, we found that E2-accessible ubiquitination sites, but not lysine residues in general, are particularly associated with kinase degradability. Finally, we extended MAPD predictions to the entire proteome to find 964 disease-causing proteins, including 278 cancer genes, that may be tractable to TPD drug development.
Show moreDec 2020 • Genome Biology
Shengqing Stan Gu, Xiaoqing Wang, Xihao Hu, Peng Jiang, Ziyi Li, Nicole Traugh, Xia Bu, Qin Tang, Chenfei Wang, Zexian Zeng, Jingxin Fu, Cliff Meyer, Yi Zhang, Paloma Cejas, Klothilda Lim, Jin Wang, Wubing Zhang, Collin Tokheim, Avinash Das Sahu, Xiaofang Xing, Benjamin Kroger, Zhangyi Ouyang, Henry Long, Gordon J Freeman, Myles Brown, X Shirley Liu
Immune checkpoint blockade (ICB) therapy has improved patient survival in a variety of cancers, but only a minority of cancer patients respond. Multiple studies have sought to identify general biomarkers of ICB response, but elucidating the molecular and cellular drivers of resistance for individual tumors remains challenging. We sought to determine whether a tumor with defined genetic background exhibits a stereotypic or heterogeneous response to ICB treatment. We establish a unique mouse system that utilizes clonal tracing and mathematical modeling to monitor the growth of each cancer clone, as well as the bulk tumor, in response to ICB. We find that tumors derived from the same clonal populations showed heterogeneous ICB response and diverse response patterns. Primary response is associated with higher immune infiltration and leads to enrichment of pre-existing ICB-resistant cancer clones. We further …
Show moreDec 2020 • Genome biology
Qian Qin, Jingyu Fan, Rongbin Zheng, Changxin Wan, Shenglin Mei, Qiu Wu, Hanfei Sun, Myles Brown, Jing Zhang, Clifford A Meyer, X Shirley Liu
We developed Lisa (http://lisa.cistrome.org/) to predict the transcriptional regulators (TRs) of differentially expressed or co-expressed gene sets. Based on the input gene sets, Lisa first uses histone mark ChIP-seq and chromatin accessibility profiles to construct a chromatin model related to the regulation of these genes. Using TR ChIP-seq peaks or imputed TR binding sites, Lisa probes the chromatin models using in silico deletion to find the most relevant TRs. Applied to gene sets derived from targeted TF perturbation experiments, Lisa boosted the performance of imputed TR cistromes and outperformed alternative methods in identifying the perturbed TRs.
Show moreDec 2020 • Optics Express
Steven A Cholewiak, Zeynep Başgöze, Ozan Cakmakci, David M Hoffman, Emily A Cooper
In near-eye display systems that support three-dimensional (3D) augmented and virtual reality, a central factor in determining the user experience is the size of the eyebox. The eyebox refers to a volume where the eye receives an acceptable view of the image with respect to a set of criteria and thresholds. The size and location of this volume are primarily driven by optical architecture choices in which designers trade-off a number of constraints, such as field of view, image quality, and product design. It is thus important to clearly quantify how design decisions affect the properties of the eyebox. Recent work has started evaluating the eyebox in 3D based purely on optical criteria. However, such analyses do not incorporate perceptual criteria that determine visual quality, which are particularly important for binocular 3D systems. To address this limitation, we introduce the framework of a perceptual eyebox. The …
Show moreNov 2020 • Blood
Carlotta Welters, Meng-Tung Hsu, Christian Alexander Stein, Livius Penter, María Fernanda Lammoglia Cobo, Kerstin Dietze, Eric Blanc, Dieter Beule, Lars Bullinger, Julian Strobel, Holger Hackstein, Armin Gerbitz, Klaus Dornmair, Thomas Blankenstein, Leo Hansmann
Multiple myeloma is a malignancy of monoclonal plasma cells accumulating in the bone marrow. The critical influence of tumor-infiltrating T cells on disease control and therapeutic responses has been shown in a variety of malignancies, however, the role of multiple myeloma bone marrow-infiltrating T cells is incompletely understood. Although it has been shown that multiple myeloma neo-antigen-specific T cells can be expanded in vitro, little is known about functions and specificities of clonally expanded multiple myeloma-infiltrating bone marrow T cells.Here we asked at the single cell level whether clonally expanded T cells i) were detectable in multiple myeloma bone marrow and peripheral blood, ii) showed characteristic immune phenotypes, and iii) recognized antigens selectively presented on multiple myeloma cells.A total of 6,744 single bone marrow T cells from 13 treatment-naïve patients were index …
Show moreNov 2020 • Blood
Jacqueline S Garcia, Yael Flamand, Benjamin K Tomlinson, Michael Keng, Lourdes M Mendez, Samer Khaled, Asad Bashey, Andrew M Brunner, Alexandra Savell, Donna Neuberg, Ilene Galinsky, Marlise R Luskin, David P Steensma, Martha Wadleigh, Eric S Winer, David E Avigan, Nicole Cullen, Scott Rodig, Livius Penter, R Coleman Lindsley, Stephanie Andrews, Matthew S Davids, Catherine J Wu, Richard M Stone, Daniel J DeAngelo, Robert J Soiffer
Background: CTLA-4 blockade with ipilimumab (IPI) has modest activity in hematologic malignancies relapsed post allogeneic hematopoietic cell transplantation (allo-HCT) (Davids M, NEJM). Adding decitabine (DAC) to IPI may increase efficacy of this approach in myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), and we further asked the extent to which alloreactivity contributed to this activity. Here, we present safety (Table 1) and clinical activity (Figure 1) from a phase I, multicenter, investigator-initiated study (CTEP 10026) of DAC plus IPI in pts with R/R MDS/AML with (Arm A) and without (Arm B) prior HCT.Methods: Pts ≥ 18 y with R/R MDS (≥ 5% blasts), R/R AML or untreated secondary AML were eligible. Prior HMA was permitted but trial was later amended to exclude those with disease progression on HMA therapy within 12 weeks of study entry. Pts post allo-HCT (Arm A) were required to …
Show moreNov 2020 • Blood, The Journal of the American Society of Hematology 136 (Supplement 1 …, 2020
Livius Penter, Yi Zhang, Alexandra Savell, Srinika Ranasinghe, Teddy Huang, Nicoletta Cieri, Satyen H Gohil, Wandi Zhang, Shuqiang Li, Robert Zeiser, Haesook T Kim, Kenneth J Livak, Jerome Ritz, Donna S Neuberg, Robert J Soiffer, X Shirley Liu, Matthew S Davids, Pavan Bachireddy, Catherine J Wu
Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains an unmet medical need. The ETCTN 9204 study evaluated in 71 study subjects if immune checkpoint blockade with anti-CTLA-4 (Ipilimumab (Ipi), n = 43) or anti-PD-1 (Nivolumab (Nivo), n = 28) antibodies could stimulate graft-versus-leukemia (GvL) responses in this setting. We focused mainly on patients (pts) with relapsed AML/MDS, which constituted the majority of pts (n = 38; 54%). Ipi induced both long-term complete remissions (CR; n = 3) and transient CRs (TR; n = 3), while Nivo did not generate any CRs, but 4 patients demonstrated partial remissions (PR).To define the molecular features associated with response to Ipi, we performed bulk transcriptomic analyses of formalin-fixed paraffin-embedded biopsies of sites of AML/MDS involvement (n = 35) collected before and after Ipi treatment from 13 pts. Our analysis of matched …
Show moreNov 2020 • Blood, The Journal of the American Society of Hematology 136 (Supplement 1 …, 2020
Livius Penter, Yi Zhang, Alexandra Savell, Srinika Ranasinghe, Teddy Huang, Nicoletta Cieri, Satyen H Gohil, Wandi Zhang, Shuqiang Li, Robert Zeiser, Haesook T Kim, Kenneth J Livak, Jerome Ritz, Donna S Neuberg, Robert J Soiffer, X Shirley Liu, Matthew S Davids, Pavan Bachireddy, Catherine J Wu
Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains an unmet medical need. The ETCTN 9204 study evaluated in 71 study subjects if immune checkpoint blockade with anti-CTLA-4 (Ipilimumab (Ipi), n = 43) or anti-PD-1 (Nivolumab (Nivo), n = 28) antibodies could stimulate graft-versus-leukemia (GvL) responses in this setting. We focused mainly on patients (pts) with relapsed AML/MDS, which constituted the majority of pts (n = 38; 54%). Ipi induced both long-term complete remissions (CR; n = 3) and transient CRs (TR; n = 3), while Nivo did not generate any CRs, but 4 patients demonstrated partial remissions (PR). To define the molecular features associated with response to Ipi, we performed bulk transcriptomic analyses of formalin-fixed paraffin-embedded biopsies of sites of AML/MDS involvement (n = 35) collected before and after Ipi treatment from 13 pts. Our analysis of …
Show moreNov 2020 • Blood 136, 34-35, 2020
Livius Penter, Yi Zhang, Alexandra Savell, Srinika Ranasinghe, Teddy Huang, Nicoletta Cieri, Satyen H Gohil, Wandi Zhang, Shuqiang Li, Robert Zeiser, Haesook T Kim, Kenneth J Livak, Jerome Ritz, Donna S Neuberg, Robert J Soiffer, X Shirley Liu, Matthew S Davids, Pavan Bachireddy, Catherine J Wu
Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains an unmet medical need. The ETCTN 9204 study evaluated in 71 study subjects if immune checkpoint blockade with anti-CTLA-4 (Ipilimumab (Ipi), n = 43) or anti-PD-1 (Nivolumab (Nivo), n = 28) antibodies could stimulate graft-versus-leukemia (GvL) responses in this setting. We focused mainly on patients (pts) with relapsed AML/MDS, which constituted the majority of pts (n = 38; 54%). Ipi induced both long-term complete remissions (CR; n = 3) and transient CRs (TR; n = 3), while Nivo did not generate any CRs, but 4 patients demonstrated partial remissions (PR). To define the molecular features associated with response to Ipi, we performed bulk transcriptomic analyses of formalin-fixed paraffin-embedded biopsies of sites of AML/MDS involvement (n = 35) collected before and after Ipi treatment from 13 pts. Our analysis of …
Show moreNov 2020 • Clinical Cancer Research
Sailing Shi, Shengqing Gu, Tong Han, Wubing Zhang, Lei Huang, Ziyi Li, Deng Pan, Jingxin Fu, Jun Ge, Myles Brown, Peng Zhang, Peng Jiang, Kai W Wucherpfennig, X Shirley Liu
Purpose:Immune checkpoint blockade has shown remarkable efficacy, but in only a minority of patients with cancer, suggesting the need to develop additional treatment strategies. Aberrant glycosylation in tumors, resulting from the dysregulated expression of key enzymes in glycan biosynthesis, modulates the immune response. However, the role of glycan biosynthesis enzymes in antitumor immunity is poorly understood. We aimed to study the immunomodulatory effects of these enzymes.Experimental Design:We integrated transcriptional profiles of treatment-naïve human tumors and functional CRISPR screens to identify glycometabolism genes with immunomodulatory effects. We further validated our findings using in vitro coculture and in vivo syngeneic tumor growth assays.Results:We identified MAN2A1, encoding an enzyme in N-glycan maturation, as a key immunomodulatory gene. Analyses of public …
Show moreOct 2020 • Trends in Biochemical Sciences, 2020
Clifford A Meyer, X Shirley Liu
This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.
Show moreOct 2020 • Journal of Vision
Martin Banks, Vivek Labhishetty, Steven Cholewiak
Conventional wisdom is that accommodation in humans exhibits significant errors. When the stimulus is far, the eye is thought to focus too near (“lead of accommodation”). When the stimulus is near, it focuses too far (“lag”). These errors are as large as 1 diopter, which should produce noticeably blurred imagery. But viewers typically do not experience the blur expected from such leads and lags. We re-examined this phenomenon by measuring accommodation objectively and subjectively. Objective measurements are based on measurements of light reflected off the retina. Subjective measurements are based on the viewer performing a visual task; they are more valid because they involve the whole visual process. We used a custom varifocal display apparatus to present accommodative stimuli to six young adults. On each trial, subjects fixated and focused on a Maltese cross at a distance of 0, 2, 4 or 6D. A …
Show moreOct 2020 • The EMBO Journal
Sunny Z Wu, Daniel L Roden, Chenfei Wang, Holly Holliday, Kate Harvey, Aurélie S Cazet, Kendelle J Murphy, Brooke Pereira, Ghamdan Al‐Eryani, Nenad Bartonicek, Rui Hou, James R Torpy, Simon Junankar, Chia‐Ling Chan, Chuan En Lam, Mun N Hui, Laurence Gluch, Jane Beith, Andrew Parker, Elizabeth Robbins, Davendra Segara, Cindy Mak, Caroline Cooper, Sanjay Warrier, Alistair Forrest, Joseph Powell, Sandra O'Toole, Thomas R Cox, Paul Timpson, Elgene Lim, X Shirley Liu, Alexander Swarbrick
The tumour stroma regulates nearly all stages of carcinogenesis. Stromal heterogeneity in human triple‐negative breast cancers (TNBCs) remains poorly understood, limiting the development of stromal‐targeted therapies. Single‐cell RNA sequencing of five TNBCs revealed two cancer‐associated fibroblast (CAF) and two perivascular‐like (PVL) subpopulations. CAFs clustered into two states: the first with features of myofibroblasts and the second characterised by high expression of growth factors and immunomodulatory molecules. PVL cells clustered into two states consistent with a differentiated and immature phenotype. We showed that these stromal states have distinct morphologies, spatial relationships and functional properties in regulating the extracellular matrix. Using cell signalling predictions, we provide evidence that stromal‐immune crosstalk acts via a diverse array of immunoregulatory molecules …
Show moreOct 2020 • Journal of Vision
Martin Banks, Vivek Labhishetty, Steven Cholewiak
Conventional wisdom is that accommodation in humans exhibits significant errors. When the stimulus is far, the eye is thought to focus too near (“lead of accommodation”). When the stimulus is near, it focuses too far (“lag”). These errors are as large as 1 diopter, which should produce noticeably blurred imagery. But viewers typically do not experience the blur expected from such leads and lags. We re-examined this phenomenon by measuring accommodation objectively and subjectively. Objective measurements are based on measurements of light reflected off the retina. Subjective measurements are based on the viewer performing a visual task; they are more valid because they involve the whole visual process. We used a custom varifocal display apparatus to present accommodative stimuli to six young adults. On each trial, subjects fixated and focused on a Maltese cross at a distance of 0, 2, 4 or 6D. A …
Show more